## Claims

1. A radiolabeled growth hormone secretagogue comprising at least one compound of the formula:

$$\begin{array}{c|c}
O & O \\
N & N \\
N & N \\
R^2 & N \\
R^2 & N \\
R^3 & R^6
\end{array}$$

$$\begin{array}{c}
N & N \\
N & N$$

5

wherein  $R^1$  to  $R^6$  are independently of each other H or T, and wherein at least one of R1 to R6 are T.

- 2. The radiolabeled growth hormone secretagogue of claim 1, wherein the specific activity of the radiolabeled growth hormone secretagogue is between 86.4 Ci/mmole and 115.2 Ci/mmole.
  - 3. The radiolabeled growth hormone secretagogue of claim 2, wherein the specific activity of the radiolabeled growth hormone secretagogue is 97.5 Ci/mmole.

15

- 4. Use of a radiolabeled growth hormone secretagogue of any one of claims 1 to 3 for identifying a compound that can bind to a growth hormone secretagogue receptor.
- 5. Use of a radiolabeled growth hormone secretagogue of any one of claims 1 to 3 for identifying a cellular receptor as a growth hormone secretagogue receptor.

- 6. Use of a radiolabeled growth hormone secretagogue of any one of claims 1 to 3 for identifying the activity of a compound as a growth hormone secretagogue.
- 7. A process of synthesizing a radiolabeled growth hormone secretagogue which comprises reacting a compound having a formula:

with  $X-\alpha$ -aminoisobutyric acid- [methyl-T], where X is defined as a protecting group which is subsequently removed if present and salts are formed if desired.

- 10 8. A method of identifying a cellular receptor as a growth hormone secretagogue receptor comprising contacting a host suspected to express a growth hormone secretagogue receptor with the radiolabeled growth hormone secretagogue of any one of claims 1 to 3 and determining whether binding has occurred.
- 9. A method for identifying a compound that can bind to a growth hormone secretagogue receptor comprising contacting said compound with a host expressing a growth hormone secretagogue receptor in the presence of the radiolabeled growth hormone secretagogue of any one of claims 1 to 3 and monitoring whether the compound influences the binding of the radiolabeled growth hormone secretagogue of any one of claims 1 to 3 to the growth hormone secretagogue receptor.

WO 2005/000362 PCT/EP2004/006567

- 10. A method for identifying the activity of a compound as a growth hormone secretagogue comprising contacting the compound suspected of having activity as a growth hormone secretagogue with a host expressing a growth hormone secretagogue receptor in the presence of the radiolabeled growth hormone secretagogue of any one of claims 1 to 3 and monitoring whether the compound suspected of having activity as a growth hormone secretagogue influences the binding of the radiolabeled growth hormone secretagogue of any one of claims 1 to 3 to the growth hormone secretagogue receptor.
- 10 11. A compound identified by the methods of any one of claims 9 or 10, or pharmaceutically acceptable salts thereof.
  - 12. A pharmaceutical composition comprising a compound of claim 11 and a pharmaceutically acceptable carrier.
  - 13. The radiolabeled ligand, compounds, methods, process, uses and composition substantially as hereinbefore described, especially with reference to the foregoing examples.

15